Eyenuk is a leading medical AI company focused on developing and deploying artificial intelligence technologies for real-time, automated disease detection from medical imaging. Its flagship product, EyeScreen, is an autonomous AI system designed to detect diabetic retinopathy in retinal images, providing a fast, reliable, and accessible solution for eye disease screening.
The company’s mission is to prevent vision loss and blindness through early detection of eye diseases using scalable, AI-powered diagnostic tools. With global regulatory clearances, including FDA 510(k) authorization in the United States, CE marking in Europe, and approvals in other international markets, Eyenuk’s solutions are trusted by primary care providers, eye clinics, and national health systems worldwide.
Features
The core product from Eyenuk is EyeScreen for Diabetic Retinopathy, a fully autonomous AI system that analyzes retinal images and provides diagnostic assessments without the need for clinician input. This feature enables frontline healthcare providers to screen patients for diabetic retinopathy during routine visits, especially in non-eye care settings like primary care clinics.
EyeScreen delivers immediate diagnostic results at the point of care. It supports standard non-mydriatic fundus cameras, requiring only a retinal image capture to begin analysis. Once the image is acquired, the system runs the AI algorithm and provides a report in under a minute.
The system is also FDA-cleared to operate autonomously, which means it can make clinical decisions without oversight from an ophthalmologist or optometrist. This capability is particularly valuable in regions where eye care specialists are scarce.
Beyond diabetic retinopathy, Eyenuk is expanding its platform to support detection of other eye diseases such as age-related macular degeneration (AMD) and glaucoma, further strengthening its position in AI-powered ocular diagnostics.
The platform integrates with electronic health records (EHR) and includes a user-friendly web-based interface that simplifies workflow for medical assistants and healthcare providers.
How It Works
The process begins with capturing high-quality retinal images using a compatible fundus camera. The images are uploaded to the EyeScreen platform via a secure web interface. Once uploaded, the AI model automatically analyzes the images for signs of diabetic retinopathy.
Within seconds, the system classifies the results into categories, such as “No Diabetic Retinopathy Detected” or “Referable Diabetic Retinopathy Detected.” This allows the healthcare provider to give immediate feedback to the patient, reducing delays associated with traditional manual grading.
Because the system is autonomous, no eye care professional is required to interpret the images. EyeScreen is designed for use by trained non-specialist staff, making it suitable for broad deployment in primary care or diabetes clinics.
The diagnostic report can be stored in the EHR, printed, or shared with specialists for follow-up referrals, helping ensure timely and coordinated care.
Use Cases
Eyenuk’s technology is most commonly used in primary care clinics and diabetes centers, where early screening for diabetic retinopathy is essential but ophthalmologists are not always available. The autonomous nature of the system enables screening during routine checkups, reducing the need for separate eye appointments and improving patient compliance.
EyeScreen is also used by retail health providers, such as pharmacies or vision centers, to offer walk-in diabetic retinopathy screening. This increases access to screening for underserved or rural populations.
National health programs can use Eyenuk’s scalable solution for population-level screening, integrating it with public health infrastructure to reduce the incidence of preventable blindness. The system’s speed and autonomy make it ideal for large-scale deployment.
Specialty clinics and hospitals use Eyenuk’s solutions to enhance efficiency by pre-screening patients before referral to ophthalmologists, helping prioritize those in need of urgent treatment.
Pricing
Eyenuk does not publish standard pricing information on its website. Pricing is typically based on the size of the practice, number of patients, hardware requirements, and licensing terms.
The company offers a per-scan pricing model or subscription-based options, depending on the provider’s needs. Interested healthcare providers are encouraged to contact Eyenuk directly for a customized quote and product demonstration.
Strengths
A major strength of Eyenuk is its status as a fully autonomous AI system with FDA 510(k) clearance, making it a clinically validated tool that does not require a human reader. This significantly improves access to early diabetic eye disease screening, especially in low-resource settings.
The platform delivers instant results, enabling same-visit diagnosis and action. This reduces patient drop-off rates and supports better long-term outcomes by facilitating timely treatment.
Eyenuk’s system is camera-agnostic, meaning it can work with a variety of commercially available retinal imaging devices, reducing the barrier to entry for clinics that already have imaging equipment.
The company’s global regulatory footprint—including approvals in the US, EU, and other markets—demonstrates its commitment to compliance and safety, making it a reliable partner for healthcare systems worldwide.
Drawbacks
One drawback is that Eyenuk currently focuses primarily on diabetic retinopathy, although the company is expanding its capabilities to cover additional diseases. Clinics looking for multi-disease AI solutions may need to wait until those new features are fully commercialized.
Another limitation is the lack of transparent pricing, which may hinder decision-making for smaller practices or providers exploring AI tools for the first time.
Integration with existing EHR systems may require technical assistance, and although the platform is designed for ease of use, initial training is necessary to ensure staff can capture high-quality retinal images.
Finally, while the system is autonomous, its performance is dependent on image quality, and poor-quality images may lead to inconclusive results, requiring repeat scans or referrals.
Comparison with Other Tools
Eyenuk competes with other autonomous AI platforms such as IDx-DR (now Digital Diagnostics) and Retina-AI Health. Like IDx-DR, Eyenuk’s EyeScreen is FDA-cleared for autonomous use, putting it in the top tier of AI ophthalmic diagnostics.
Compared to IDx-DR, Eyenuk supports a broader range of camera systems, which may give it an edge in terms of flexibility and cost-effectiveness. Both platforms deliver rapid diagnostic results, but Eyenuk’s global presence and CE marking give it broader applicability in international markets.
Retina-AI and other vision AI tools may offer decision support rather than autonomous diagnostics, which sets Eyenuk apart in terms of independence from human oversight.
While most competitors are focused on diabetic retinopathy alone, Eyenuk’s roadmap includes expanded capabilities for AMD and glaucoma, positioning it for long-term competitiveness in comprehensive eye screening.
Customer Reviews and Testimonials
While direct testimonials are limited on the official website, Eyenuk has received recognition from healthcare providers and industry reviewers for its ease of use, fast implementation, and impact on screening compliance. The platform has been deployed in real-world settings such as primary care networks, demonstrating measurable improvements in early disease detection.
Publications and case studies from deployments in the United States, India, and Europe highlight its role in increasing screening coverage and reducing referrals to specialists, improving patient flow and reducing healthcare costs.
Eyenuk has received awards and recognition from health innovation competitions and regulatory bodies, further validating its contribution to AI in healthcare.
Conclusion
Eyenuk is a pioneering force in AI-powered eye screening, delivering autonomous diagnostic tools that improve access to diabetic retinopathy detection and reduce the burden on eye care professionals. With its FDA-cleared EyeScreen platform, Eyenuk offers a practical, scalable solution for clinics, hospitals, and health systems aiming to combat preventable blindness.
By enabling point-of-care screening with instant results and minimal infrastructure, Eyenuk empowers non-specialists to play a critical role in early eye disease detection. Its expanding capabilities for AMD and glaucoma signal a strong future roadmap in AI-driven ophthalmology.
For healthcare providers looking to integrate AI into routine care and improve patient outcomes, Eyenuk offers a clinically validated, globally trusted platform. Visit the official website at https://www.eyenuk.com to learn more or request a demonstration.
